Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.
7.1.2026 11:07:00 CET | Business Wire | Press Release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January.
Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use.
Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity.
Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy, VIT is the only treatment that can prevent systemic inflammatory reactions to bee or wasp stings and significantly improve quality of life, even for people with less severe allergic reactions.2
“Entomon’s activities complement Stallergenes Greer’s portfolio and strengthen our control of critical allergen extracts, notably Hymenoptera venoms used in allergen immunotherapy” stated Dr. Andreas Amrein, Chairman and CEO of Stallergenes Greer. “This acquisition secures long-term access to high-quality venom extracts in a market constrained by limited global capacity. It also builds on our existing partnerships and supports a diversified model for venom immunotherapy components. By reinforcing supply chain diversification and building on our well-established position in venom immunotherapy with Albey®, we strengthen our ability to support patients and healthcare professionals worldwide and deliver on our long-term commitment to high-standard, reliable allergy care. We are delighted to welcome Entomon to the Stallergenes Greer Group.”
“Becoming part of Stallergenes Greer marks a transformative moment for Entomon. It is a testament to our expertise in the extraction of pure Hymenoptera venom and our ability to deliver high-quality raw materials which are essential for life-saving allergen immunotherapies. We are excited to embark on this new chapter,” declared Dr. Elisabetta Francescato, CEO and founder of Entomon s.r.l.
About hymenoptera venom allergies
Stinging-insect venom sensitisation is common in the general population (between 9.3% and 28.7%), and more than half of the population will be stung by an insect at least once in their lifetime depending on the living environment and type of activity.34
Venom allergy is an IgE-mediated hypersensitivity reaction triggered by stings from insects such as bees, wasps, hornets, or other Hymenoptera species. While local reactions are common and usually mild, venom-allergic individuals can experience systemic responses ranging from widespread hives to severe anaphylaxis. Hymenoptera venom allergy is the primary cause of anaphylaxis in adults in Europe, being responsible for 48.2% of cases and 20.2% in children worldwide5. Based on national mortality surveillance, fatal anaphylaxis due to Hymenoptera stings accounts for approximately 72 deaths per year in the United States6, while European data indicate a comparable burden of about 73 deaths annually across 32 countries7.
Diagnosis relies on a combination of clinical history, skin testing, and specific IgE measurement to identify the responsible insect. Venom immunotherapy is the only treatment proven to modify the natural course of venom allergy. It provides long-term protection by inducing immune tolerance8, markedly reducing the risk of systemic reactions to future stings and improving patients’ quality of life.
Because Hymenoptera venoms differ by species, the availability and quality of venom extracts are essential to enable accurate diagnosis and effective immunotherapy, ensuring patients receive targeted and reliable treatment.
About Albey® Venoms
Albey® Venoms are standardised purified extracts derived from hymenoptera species, including honeybee (Apis mellifera), yellow jacket (Vespula spp.), and paper wasp (Polistes spp.). These extracts are specifically designed for Venom Immunotherapy (VIT), the only proven treatment to prevent severe systemic allergic reactions.
Albey® holds marketing authorisations in France, Italy, Australia and New Zealand. It is also available in Italy under ope legis status.
About Entomon
Based in Florence (Italy), Entomon s.r.l. is a privately held company established by leading biologists and naturalists with deep expertise in the study of insects and their impact on human health and activity. The company specialises in the extraction of pure insect venom extracts for diagnostic reagents and venom immunotherapy for individuals with insect sting allergies. Entomon is the sole producer in Europe of insect of pure, certified Hymenoptera venom extracts. For more information, please visit: www.entomon.it
About Stallergenes Greer
Headquartered in Baar (Switzerland), Stallergenes Greer is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy products and services. Supported by more than 100 years of expertise and innovation, our products are available for patients in over 40 countries. For more information, please visit www.stallergenesgreer.com.
1 Hymenoptera (bee and wasp) Stevens et al. Recent insights into the mechanisms of anaphylaxis. Curr Opin Immunol. 2023 Apr;81
2 EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy (Allergy. 2018 Apr;73(4):744-764)
3 Bilò, M. B., Pravettoni, V., Bignardi, D., Bonadonna, P., Mauro, M., Novembre, E., ... & Pastorello, E. A. (2019). Hymenoptera venom allergy: management of children and adults in clinical practice. Journal of investigational allergology & clinical immunology, 29(3), 180-205.
4 Golden, D. B., Demain, J., Freeman, T., Graft, D., Tankersley, M., Tracy, J., ... & Wallace, D. (2017). Stinging insect hypersensitivity: a practice parameter update 2016. Annals of Allergy, Asthma & Immunology, 118(1), 28-5
5 Rueff et al., (2023) Diagnosis and treatment of Hymenoptera venom allergy
6 QuickStats: Number of Deaths from Hornet, Wasp, and Bee Stings Among Males and Females — National Vital Statistics System, United States, 2011–2021. MMWR Morb Mortal Wkly Rep 2023;72:756.
7 Feás, X.; Vidal, C.; Remesar, S. What We Know about Sting-Related Deaths? Human Fatalities Caused by Hornet, Wasp and Bee Stings in Europe (1994–2016). Biology 2022, 11, 282. https://doi.org/10.3390/biology11020282
8 Golden et al. J Allergy Clin Immunol. 2011 Apr ;127(4):852-4.e1-23
View source version on businesswire.com: https://www.businesswire.com/news/home/20260107561851/en/
Contacts
Stallergenes Greer
Communications
Catherine Kress
Tel: +33 (0)1 55 50 26 05
Email: catherine.kress@stallergenesgreer.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Canada to Join the NATO Innovation Fund to Advance the Local Defence, Security and Resilience Ecosystem21.11.2026 17:00:00 CET | Press Release
Canada announced today it is joining the NATO Innovation Fund, becoming the 25th Allied nation to commit to backing deep tech innovation to address the needs of NATO nations. The Government of Canada is committing EUR 64,590,000 (approximately CAD $100 million) to the firm, with the Business Development Bank of Canada (BDC) holding and managing Canada’s investment in the Fund. This brings total commitments to the NATO Innovation Fund to more than EUR 1.1 billion. Canadian membership will give domestic innovators access to patient capital, opportunities to accelerate the adoption of their technology by governments and businesses across the Alliance, a large network of co-investors, and lessons learned from the NIF’s work to date across 24 participating nations. “Canada has the talent, the innovation, and the ambition to be a global leader in defence and security. The NATO Innovation Fund is helping turn that potential into real capabilities by connecting Canadian innovators with the inv
Persona Earns CEN/TS 18099 High Certification for Injection Attack Detection21.11.2026 15:30:00 CET | Press Release
Persona, the leading global identity platform, today announced that its Android SDK has earned CEN/TS 18099 High certification for injection attack detection (IAD). High certification is the top level of the European standard. The evaluation was run by CLR CERT, the certification body of Cabinet Louis Reynaud (CLR) Labs. CLR Labs is accredited under ISO/IEC 17025, the international standard for testing laboratories, and it edits CEN/TS 18099. This certificated injection attack detection is available to all Persona customers and can be activated by working with Persona's team. Injection attacks skip the camera entirely. Instead of holding a photo or mask up to a lens, fraudsters use virtual cameras, emulators and tampered devices to feed stolen, manipulated, or AI-generated media straight into the verification flow. To the system, the result looks like a real live capture, and traditional liveness checks aren't built to catch it. "Our customers are facing more sophisticated deepfakes, f
Picsart Opens the AI Behind Its Platform to Developers & Businesses20.11.2026 20:54:00 CET | Press Release
Picsart, the AI media production and distribution platform backed by Sequoia Capital and SoftBank Vision Fund 2, today launched Picsart Platform - a multimodal creative AI hub that gives developers the technology behind the platform used by more than 100 million people each month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120520968/en/ Picsart Opens the AI Behind Its Platform to Developers & Businesses. They can now build their own video, audio, image features using 250+ models from 30+ providers, alongside Picsart's own editing models, through one API, CLI or MCP server. As new video and image models launch every few weeks, managing separate APIs, API keys, and billing systems creates a fragmented ecosystem. By offering unified access to creative tools, Picsart Platform eliminates fragmentation for all creators, spanning independent developers and corporate marketing teams and studios, by providing access to over 25
NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 18:45:00 CET | Press Release
NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create extraordinary moments for Owners, both in the air and on the ground in Kitzbühel. “Kitzbühel is synonymous
Frontgrade Technologies Help Power Critical Computing and Electronics Aboard NASA’s Roman Space Telescope20.11.2026 18:40:00 CET | Press Release
Frontgrade today announced that technologies from across its space electronics portfolio are supporting multiple mission-critical systems aboard NASA’s Nancy Grace Roman Space Telescope, which successfully launched on August 30, 2026. Roman is NASA’s flagship astrophysics observatory designed to investigate dark energy, discover exoplanets and explore the evolution of the universe. Its onboard electronics include radiation-hardened processors and microelectronics, providing critical processing, communications, power-management and control functions across the spacecraft. At the centre of Roman’s computing architecture are Frontgrade Gaisler’s GR740 and GR712RC processors. The GR740 radiation-hardened quad-core LEON4FT processor serves as the computing engine for the Wildcat Processor Card, used in the spacecraft’s primary and redundant Command and Data Handling systems as well as the Instrument Command and Data Handling systems for both the Wide Field Instrument and Coronagraph Instrum
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom